NEW HAVEN | Jotup

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Retrieved on:

Thursday, May 9, 2024

Congress, CDK, Proteolysis, HER2, Breast cancer, Oncology, ARVN, ESMO, Chimera, Patient, Team Impulse, Poster, Clinical trial, PROTAC

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.

Key Points:

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany.
Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Poster session details are as follows:
Time: 12:00 – 1:00 p.m. CET/ 6:00 – 7:00 a.m.
ET
Poster Title and Number: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: updated phase 1b cohort results, Poster 218P
Presentation Type and Abstract Number: Abstract, 453
Poster Title and Number: TACTIVE-K: phase 1b/2 study of vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer, Poster 264
Presentation Type and Abstract Number: Trial-in-Progress (TiP), 488

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on:

Thursday, May 9, 2024

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter of 2024.

Key Points:

ET today
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced its financial results for the first quarter of 2024.
Net Loss: BioXcel Therapeutics had a net loss of $26.8 million for the first quarter of 2024, compared to a net loss of $52.8 million for the same period in 2023.
BioXcel Therapeutics will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.
ET to discuss its first quarter 2024 financial results.

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

Tuesday, May 7, 2024

NEW HAVEN, Conn., May 07, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Key Points:

Announced the resignation of Chief Financial Officer and Treasurer, Sean Cassidy, effective February 29, 2024.
Research and Development Expenses: Research and development expenses were $84.3 million for the quarter ended March 31, 2024, as compared with $95.3 million for the quarter ended March 31, 2023.
General and Administrative Expenses: General and administrative expenses were $24.3 million for the quarter ended March 31, 2024, as compared with $24.9 million for the quarter ended March 31, 2023.
Revenues: Revenues were $25.3 million for the quarter ended March 31, 2024 as compared with $32.5 million for the quarter ended March 31, 2023.

Precipio Secures a short-term $500K Credit Facility

Retrieved on:

Monday, May 6, 2024

Insurance, Change Healthcare, Bank

Many healthcare businesses, including Precipio’s Diagnostic Services division, rely on Change Healthcare (CH) to submit bills and collect cash from various payors and insurance companies for the services they provide.

Key Points:

Many healthcare businesses, including Precipio’s Diagnostic Services division, rely on Change Healthcare (CH) to submit bills and collect cash from various payors and insurance companies for the services they provide.
As mentioned on the call, payments from customers of Precipio’s Products division are not processed through CH and were not impacted by the cybersecurity event.
Under the terms of the facility, the company will draw down the first $250K immediately; and can access an additional $250K in a future time, at its discretion.
We are committed to the continued path towards profitability, and believe this is a temporary bump in that road.”

Local Infusion Opens Infusion Center in New Haven, Connecticut, the Seventh Location to Open in New England

Retrieved on:

Monday, April 29, 2024

Health, Wi-Fi, Medicine, Entrepreneurship, Patient, Route 15, Patient satisfaction, Medical device

NASHVILLE, Tenn., April 29, 2024 /PRNewswire-PRWeb/ -- Local Infusion, a technology-driven provider for patients with chronic autoimmune diseases on specialty infusion therapy, announced the opening of a state-of-the-art infusion center in New Haven, Connecticut.

Key Points:

We are excited about our continued expansion into Connecticut with our New Haven location — expanding access to affordable, high-quality infusion therapy care to the great state of Connecticut.
Local Infusion New Haven was built to meet the growing demand for world-class infusion care by patients and employers in the area.
The opening of Local Infusion New Haven quickly follows the company's first location in Rocky Hill earlier this month.
Prior to that, Local Infusion opened its Bangor, ME location in February 2024, South Portland, ME location in August 2023, Augusta, ME location in May 2023, its Bedford, NH location in March 2023, and its Concord, NH location in January 2023.

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

Retrieved on:

Thursday, April 25, 2024

Intelligence, Therapy, Webcast

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.

Key Points:

NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.
BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to discuss the Company’s financial results and provide a general business update.

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Retrieved on:

Wednesday, April 24, 2024

ARVN, Executive, Patient, Growth, Management

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer.

Key Points:

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer.
Dr. Teel currently serves as Arvinas’ interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston, Ph.D. Dr. Teel will remain in these interim roles at Arvinas while the board of directors continues its search for a permanent Chief Financial Officer and Treasurer.
"We are delighted to announce Randy's promotion to Chief Business Officer,” said John Houston, Ph.D., Chairperson, President and Chief Executive Officer at Arvinas.
At Arvinas, in addition to finance, he also leads corporate strategy, business development, investor relations, and communications.

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

Retrieved on:

Wednesday, April 24, 2024

Cure, Safety, Tumor microenvironment, Intelligence, PDAC, ASCO, Merck & Co., Society, Poster, Annual general meeting, Therapy, Merck, Pharmaceutical industry

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that a late-breaking abstract with preliminary findings from the Phase 2 investigator-sponsored trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) has been selected for presentation in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.

Key Points:

The meeting will take place from May 31 to June 4, 2024 in Chicago, IL.
On February 6, 2024, BioXcel Therapeutics announced the completion of patient enrollment in the safety lead-in portion of the trial.
Through its OnkosXcel Therapeutics immuno-oncology subsidiary, BioXcel Therapeutics is collaborating with Dr. Louis M. Weiner, director of the Lombardi Comprehensive Cancer Center, and Dr. Benjamin Weinberg, principal investigator of the study.
BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Retrieved on:

Monday, April 22, 2024

FDA, Patient, Dexmedetomidine, Safety, Agitation, Food, Bipolar disorder, Intermittent explosive disorder, Intelligence, Schizophrenia, Medicine, New product development, DSM-IV codes, Therapy, Type, Pharmaceutical industry

NEW HAVEN, Conn., April 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced additional details regarding the planned design of its SERENITY At-Home Phase 3 trial*to evaluate BXCL501, the Company’s investigational, proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with bipolar disorders or schizophrenia in the home setting. The Company’s plan to conduct this trial using a 120 mcg dose is based on feedback received from the U.S. Food and Drug Administration (FDA) following the recent receipt of agency minutes from the Type C meeting held on March 6, 2024.

Key Points:

The outpatient trial is expected to enroll a total of approximately 200 patients with agitation associated with bipolar disorder or schizophrenia.
Patients will self-administer 120 mcg of BXCL501 or placebo when agitation episodes occur over the trial period.
The primary objective is safety with efficacy measures as exploratory endpoints to evaluate use in the outpatient setting.
A corporate presentation, including information on the SERENITY program, is available on the Investors section of the Company’s website: bioxceltherapeutics.com.

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

Retrieved on:

Thursday, April 11, 2024

Sale, License, NVS, ARVN, Goldman Sachs, Research, Prostate cancer, Patient, PROTAC, Pharmaceutical industry

NEW HAVEN, Conn., April 11, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has entered into an exclusive strategic license agreement with Novartis (NYSE: NVS) for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.

Key Points:

The transaction also includes an asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis.
“We believe the expertise and scale of Novartis will broaden the development of ARV-766 and its potential to be a first- and best-in-class treatment for patients with prostate cancer.
Under the License Agreement, Arvinas is eligible to receive additional development, regulatory, and commercial milestones of up to $1.01 billion, as well as tiered royalties for ARV-766.
Goldman Sachs & Co. LLC is acting as the exclusive financial advisor to Arvinas.